About AML and FLT3-ITD
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. It begins in the bone marrow and moves into the blood. “Acute” means the cancer can progress quickly and can be fatal if not treated. “Myeloid” refers to the type of cell the cancer starts from.
About 30% of people with AML have a genetic mutation known as FLT3-ITD. People with this mutation are much more likely to have a relapse or often fail to respond to initial chemotherapy. This makes the disease more difficult to treat. However, new drugs that target the FLT3-ITD mutation are currently being developed through clinical trials.
Once diagnosed, the goal of initial treatment is to:
- Eliminate as many AML cells as possible, and
- Return blood count to normal levels
This is often accomplished through chemotherapy, radiation or a bone marrow transplant.
For more information or to see if you qualify, call 1-844-432-3892 Monday thru Friday 9AM – 6PM ET